Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Shorter Antibiotic Therapy Effective for Pyogenic Vertebral Osteomyelitis

  |  

The study investigators appear to agree with this point. They specify that results are valid for older patients (≥ 75 years), and those with severe infection. They caution, however, against extrapolating the findings of their study to patients with other vertebral osteomyelitis due to non-pyogenic microorganisms, methicillin-resistant Staphylococcus aureus, or those without microbiological identification. (posted 1/16/15)

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ADVERTISEMENT
SCROLL TO CONTINUE

References

1. Bernard L, Dinh A, Ghout I, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. 2014. Lancet. Nov. 4. doi:10.1016/S0140-6736(14)61233-2. [Epub ahead of print].

ADVERTISEMENT
SCROLL TO CONTINUE

2. Lora-Tamayo J and Murillo, O. Shorter treatments for vertebral osteomyelitis. 2014. Lancet. Nov. 5. doi:10.1016/S0140-6736(14)61936-X. [Epub ahead of print].

 

Related Articles

    Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

    Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….

    Targeted Vertebral Fracture Assessment

    A Canadian study sought to identify individuals at high fracture risk and provide them with pharmacotherapy to prevent fractures. They found the assessment of hip and lumbar dual-energy X-ray absorptiometry scans for vertebral fracture can be useful in the identification of women and men aged 70 years and older who should qualify for anti-osteoporosis treatment…